Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy
Go back to Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy| KARYOPHARM THERAP (NASDAQ: KPTI) | Delayed: 1.79 +0.02 (1.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.77 | 52 Week High | $19.41 | |||
| Open | $1.77 | 52 Week Low | $4.83 | |||
| Day High | $1.84 | P/E | N/A | |||
| Day Low | $1.76 | EPS | $-2.74 | |||
| Volume | 577,790 | |||||
